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a b s t r a c t
Drug permeability of the model drugs ketoprofen and nadolol across Caco-2 cell monolayers was deter-
mined in the absence and presence of the non-ionic surfactant Poloxamer 188 (Pluronic F68, P-188).
Stringent controls conﬁrmed that P-188 in concentrations up to 50 mg/ml did not adversely affect cell
viability or monolayer integrity. Equilibrium experiments conﬁrmed that the drugs were merely pas-
sively transported. Caco-2 permeability of both drugs was found to be decreased by the surfactant in a
concentration-dependent manner. Ultraﬁltration revealed that both drugs were associated with surfac-
tant micelles. The systematic investigation of micellization on passive absorption showed that associa-
tion of drugs with P-188 micelles appears to depress their passive permeability under conditions
where other transport mechanisms can be neglected.
 2011 Elsevier B.V. All rights reserved.
1. Introduction
Due to greater patient convenience and thus enhanced compli-
ance, the oral route is the preferred route of drug administration. In
recent years, many new chemical entities (NCEs) that are poorly
soluble in aqueous medium have been identiﬁed. Such unfavour-
able solubility characteristics are usually accompanied by poor
bioavailability with the result that modern oral dosage form design
is predominantly focussing on drug delivery systems providing
oral bioavailability enhancement. Besides selection of the most sol-
uble salt form and synthesis of prodrugs with enhanced solubility,
modiﬁcation of the solid state [1–3] is a well-acknowledged ap-
proach. Among the advanced formulations, cyclodextrins and sur-
factants or lipids are most commonly used [4–8]. Literature
illustrates the successful use of solubility-enhancing formulations
to improve the bioavailability of poorly soluble drugs [9–11],
although in some cases the opposite has been reported [12]. The
solubility-enhancing effect of surfactant-containing formulations
in the context of micellar solubilization of a drug has been thor-
oughly studied. In contrast, investigations regarding the effects of
surfactants on drug permeability remain scarce and contradictory.
However, more recently, a small number of solubilizing agents
have been studied in in vitro permeability tests. Their role was
partly to overcome recovery and detection limit challenges [13],
while also to investigate their inﬂuence on permeability [14]. In
the present literature, results are contradicting: there are indica-
tions for surfactant inﬂuences on passive drug perfusion via barrier
interaction [15], via inhibition of P-glycoprotein (P-gp) [16], via
micellar solubilization [17], ion-pair formation [18] or membrane
ﬂuidization [19]. A further complicating factor is that the Caco-2
cell permeation model employed in most of the aforementioned
studies exhibits several parallel drug transport pathways: transcel-
lular, paracellular, carrier-mediated and endo-/transcytotic trans-
port. However, a systematic investigation of the interplay of such
factors by which a surfactant may act on solubility as well as per-
meability is missing. As a result, this renders it difﬁcult to identify
precisely the direct impact of a given excipient.
Thus, for the current study, we have chosen two model drugs,
ketoprofen and nadolol, which have been described to be passively
absorbed [20,21], because we wanted to exclude interaction with
active transport systems. As a surfactant, we have chosen Polox-
amer 188 (P-188), which is commonly used in oral drug formula-
tions, mostly as a bio-enhancer [22–25], and which has shown to
have a low impact on Caco-2 cell viability [26]. For permeability
experiments, stringent controls for monolayer integrity and func-
tionality have been employed in terms of trans-epithelial electrical
resistance (TEER) measurement over time in combination with
permeability assessment of a paracellular marker (carboxyﬂuores-
cein). In our opinion, considerations regarding the integrity control
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have not been sufﬁciently taken into account in other permeability
studies when surfactants were present.
The aim of the current study was to systematically determine
the inﬂuence of the non-ionic surfactant P-188 on passive
permeability of the two poorly water soluble model drugs, keto-
profen and nadolol. In order to exclude other potential inﬂuences,
we have stringently monitored Caco-2 cell viability of the surfac-
tant, maintenance of monolayer integrity and absence of alterna-
tive pathways, such as active transport.
2. Materials and methods
2.1. Materials
Dulbecco’s modiﬁed Eagle’s medium (DMEM), foetal bovine ser-
um (FBS) and supplements were supplied by Biochrom (Berlin,
Germany). Rat tail collagen was purchased from Roche (Mannheim,
Germany). The buffer used in all experiments was Hanks’ Balanced
Salt Solution (Sigma–Aldrich Chemie GmbH, Munich, Germany)
containing KCl 0.40 g, KH2PO4 0.06 g, NaCl 8.0 g, Na2HPO4
0.048 g, D-glucose 1 g, CaCl2  2H2O 0.185 g and supplemented
with MgSO4  7H2O 0.98 g, NaHCO3 0.35 g (1000 ml) and was
adjusted to pH 7.4. Poloxamer 188 (Pluronic F68, Lutrol F68,
P-188) was kindly provided by BASF SE, Ludwigshafen, Germany.
Triton X-100, 5(6)-carboxyﬂuorescein, ketoprofen, and nadolol,
rhodamine 123 as well as all other chemicals were purchased from
Sigma–Aldrich Chemie GmbH, Munich, Germany.
2.2. Cell culture
Caco-2cellswereculturedasdescribedin [27]. Inbrief, Caco-2cells
were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (Bio-
chrom, Berlin, Germany), which was supplemented with 10% FBS,
1% non-essential amino acids, 1% pyruvate, 1% L-glutamine, 100 U/
ml penicillin and 100 lg/ml streptomycin at 37 C in 5% CO2 atmo-
sphere in equilibriumwith distilledwater. Themediumwas changed
every other day, and the cellswere split at 80% conﬂuency. For exper-
iments, cells were used at passage number 34–44.
2.3. Preparation of sample solutions
All drug and surfactant solutions were prepared in Hanks’ Bal-
anced Salt Solution (HBSS++) and were ﬁnally adjusted to pH 7.4.
In cell studies, the concentrations of the paracellular marker car-
boxyﬂuorescein, the P-gp substrate rhodamine 123 and the two
model drugs ketoprofen and nadolol were 0.02, 0.05, 2.6 and
7.5 mM, respectively. The carboxyﬂuorescein concentration of 0.2
mM was previously found to be appropriate to provide reliable
permeability data [14]. Rhodamine 123 at a concentration of 0.05
mM was found to give reproducible results in equilibrium experi-
ments (data not shown). The concentrations of the two model
drugs were chosen so as to be well below the saturation limits
(at pH 7.4) yet at the same time to yield reliably detectable receiver
concentrations during permeation studies. For additional informa-
tion regarding the model drugs, an overview of their physico-
chemical properties is provided in Table 1.
2.4. Viability studies of Caco-2 cells
For cell viability studies, the alamarBlue assay was employed.
The underlying principle is that alamarBlue, a reduction–oxida-
tion (redox) dye, monitors the reductive environment of cell
growth by being transformed into the reduced form, i.e. is trans-
formed from its blue (oxidized) to its red (reduced) form. Hereby,
it offers a quantitative analysis of cell viability measured by ﬂuo-
rescence spectroscopy. For experiments, the Caco-2 cells were
seeded on rat tail collagen-coated 96-well plates at a density of
65,000/cm2 and were used after 14 days. Cells were maintained
under the same conditions as described above. Prior to experi-
ments, the cells were washed twice with HBSS++ and were then
incubated over 6 h at 37 C with sample solutions of different con-
centrations of P-188. In case of the negative control, cells were
incubated only with HBSS++, while for the positive control, Triton
X-100 1% dissolved in HBSS++ was used. Thereafter, the cells were
washed again with HBSS++ and then the indicator dye alamarBlue
was added. After 3 h of incubation (37 C), the change of the redox
dye was determined by ﬂuorescent spectroscopy (excitation wave-
length 530 nm, emission wavelength 590 nm). Cell viability (VIAB)
was then calculated according to the following equation:
VIAB = SAMPLE/CONTROL  100%, where CONTROL is the emission
of the cells incubated with HBSS++ only and SAMPLE the emission
of cells incubated with either P-188 or Triton X-100 solutions.
2.5. Equilibrium and permeation experiments across Caco-2 cell
monolayers
For equilibrium and permeation experiments, Caco-2 cells were
seeded on rat tail collagen-coated polyester ﬁlters (Transwell Per-
meable Supports, 12 mm, Corning Inc., New York) at a density of
80,000 cells/cm2. The medium was changed every other day, and
they were used for experiments after 14–15 days. Twelve hours
prior to experiments, the supplementedDMEMwas changed tophe-
nol red-free DMEM that was unsupplemented. Before the actual
experiment, the cell monolayers were washed twice with HBSS++
and incubated for 1 h. Then, in case of equilibrium experiments,
the buffer both in the apical and basolateral compartment was re-
moved and replaced by sample solution. These experiments were
performed using the same concentration of drug dissolved in
HBSS++ (pH7.4) in theapical and thebasolateral compartment. After
incubation over 4 hwhile the culture plateswere shaken (’50 rpm),
the concentration of the drug in both compartments was measured
and comparedwith the initial concentration in order to seewhether
a directed (active) transport was involved.
For permeation experiments, the buffer in the apical compart-
ment was removed after washing and incubation and replaced by
sample solution. These experiments were performed by applying
a certain drug concentration at the apical side, whereas the baso-
lateral side contained only HBSS++. Over time periods of 3.5 h (car-
boxyﬂuorescein and nadolol) and 3 h (ketoprofen), the inserts were
moved to fresh wells containing HBSS++ at time intervals of 30–
45 min in order to ensure sink conditions. The inserts containing
plates were shaken throughout the experiment (’50 rpm). The
concentration at the basolateral side was measured. After the
experiment, the concentration at the apical side was also
quantiﬁed to check mass balance. Mass balances were in the range
of 93–99%. The cumulative amount of drug that had permeated
through the monolayer, i.e. measured in the basolateral compart-
ment, was plotted against time giving the cumulative ﬂux. When
the ﬂux reached steady state, i.e. the slope was linear, the apparent
Table 1
Physico-chemical parameters for the two model compounds.
Compound MW* pKa** log p** Aqueous
solubility***
PhEur 7.0
Ketoprofen 254.3 4.6 3.12 0.051 Practically insoluble
in water
Nadolol 309.4 9.4 0.71 8.33 Slightly soluble in
water
* Molecular weight (MW) in g/mol.
** From [37].
*** from [38] in mg/ml (unbuffered).
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permeability coefﬁcient (Papp) was calculated according the
following equation. Papp = dm/dt  (1/Ac0), where dm is the cumula-
tive amount of drug permeated by the time dt, A is the area of the
insert used and c0 is the initial donor concentration. Steady-state
conditions, i.e. linear dependency between cumulative ﬂux and
time (R2P 0.99), was found to be achieved after 1 h for both, keto-
profen and nadolol. In the case of carboxyﬂuorescein, steady state
of the ﬂux was reached after 1.5 h (R2P 0.98). For calculation of
the Papp, ﬁve remaining points of the linear parts of the ﬂux curves
were used in order to calculate the Papp values.
2.6. Trans-epithelial electrical resistance measurements
Trans-epithelial electrical resistance (TEER) measurements
were performed in a cellZscope apparatus (Nanoanalytics, Mün-
ster, Germany), an automated cell monitoring system, where cell
inserts were placed inside, and the TEER was determined by con-
tinuously measuring the frequency-dependent impedance of the
cell layer [27]. This was done in parallel (up to 24 inserts) over
time. The volume at the apical and basolateral side was 0.6 ml
and 1.0 ml, respectively.
2.7. Ultraﬁltration experiments
Ultraﬁltration experiments were performed using Amicon Ul-
tra-15 Centrifugal Filter Units with regenerated cellulose (Ultra-
cel-10) membranes (MWCO = 10 kDa), Millipore GmbH,
Schwalbach, Germany. Prior to experiments, the ﬁlter units were
ﬁlled with HBSS++ and centrifuged (25 C, 4000g, 2 min) in order
to wash the membrane ﬁlter. Sample solution was then poured
in the ﬁlter unit, and the tube was centrifuged again (25 C,
4000g, 2 min) to saturate the ﬁlter membrane. The ultraﬁltrate
was discarded. Afterwards, the tube was centrifuged a third time
(25 C, 4000g, 5 min), and the amount of drug in the ultraﬁltrate
was analysed. Preliminary experiments had been performed to en-
sure constant levels in the ultraﬁltrate (data not shown). Subse-
quently, 5-min centrifugation was chosen due to a sufﬁcient
amount of sample for analysing and reproducible concentrations
of compounds. Finally, the relative recovery was obtained by divid-
ing the ultraﬁltrate concentration by the initial concentration.
2.8. Analysis
The alamarBlue indicator dye as well as carboxyﬂuorescein
was analysed by ﬂuorescence spectroscopy using a Fluoroskan As-
cent plate reader (excitation wavelength 530 and 485 nm, emis-
sion wavelength 590 and 520 nm, respectively). Ketoprofen and
nadolol were analysed using a Dionex Ultimate 3000 HPLC with
photodiode array detection (Ultimate 3000 Photodiode Array
Detector). Separation was performed by employment of an Ac-
claim 120 (C18, 5 lm particle size, 120 Å, 4.6  250 mm) column.
Mobile phases, gradients and wavelengths are listed in Table 2. The
software used was Chromeleon 6.80, Dionex GmbH, Idstein,
Germany.
2.9. Statistical analysis
Origin 6.0 (OriginLab Corporation, Northampton, MA, USA) was
used for the statistical analysis. Comparison of two means was per-
formed by applying an unpaired t-test (two-tailed) where p < 0.05
was considered as statistical signiﬁcant.
3. Results
3.1. Cell viability and monolayer integrity of Caco-2 cells in the
presence of P-188
Prior to performance of permeation studies across Caco-2 cell
monolayers, cell viability and monolayer integrity were analysed
in the presence of increasing concentrations of P-188. All P-188
concentrations used were above the CMC (0.26% w/w) [28].
HBSS++, the buffer used in all experiments, served as a (negative)
control. Triton X-100, which is known to rapidly dissolve cell mem-
branes, served as a positive control. For viability studies, the cells
reductive capacity on alamarBlue was measured in order to con-
ﬁrm whether metabolic activity was maintained. After incubation
over 6 h with P-188 (up to 50 mg/ml), no signiﬁcant change of via-
bility as compared to the control was observed (Fig. 1). Apparently,
P-188 did not negatively affect cell viability. Furthermore, in order
to ﬁnd out whether P-188 affects the integrity of the cell mono-
layer barrier, we measured the TEER before and after adding P-
188 solution to the donor compartment and subsequently over a
time range of 4 h. As shown in Fig. 2, the TEER was not changed
in the presence of P-188 as compared to HBSS++, whereas in the
positive control, Triton X-100 caused the TEER to drop rapidly
and drastically. The decrease in TEER after incubation with HBSS++
was due to aspiration of buffer and adding of sample solutions
(t = 0) and occurred when the control as well as surfactant solu-
tions were used. This decrease was relatively low and the TEER
Table 2
HPLC parameters for ketoprofen and nadolol.
Compound Mobile phase (%) Run
time
(min)
Flow
(ml/
min)
k
(nm)
H2Oa Methanola Acetonitrilea
Ketoprofen 20 80 – 0 0.08 260
20 80 – 12
Nadolol 90 – 10 0 1.0 220
70 – 30 6
70 – 30 10
90 – 10 18
a Mobile phases contained 0.05% triﬂuoroacetic acid.
Fig. 1. Viability values obtained from alamarBlue cytotoxicity assay after incuba-
tion (6 h) with P-188 (Poloxamer 188), Triton X-100 (positive control) and HBSS++
(negative control). Data are shown as percentage of the negative control (=100%).
Values are given as mean ± SEM, n = 8. Signiﬁcant differences with HBSS++ are
marked with  (p < 0.05).
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level re-established with time. In parallel, we determined perme-
ability of the paracellular marker carboxyﬂuorescein. Permeability
values were not enhanced in the presence of various P-188 concen-
trations up to 50 mg/ml (see Fig. 3). Maintenance of high TEER val-
ues and low paracellular marker permeability, as observed here
with all P-188 concentrations, is usually interpreted as an indica-
tion for closed (intact) tight junctions. This is consistent with other
Caco-2 cell studies, where different poloxamers were used [29].
Surprisingly, carboxyﬂuorescein permeability was found to be re-
duced at the highest P-188 concentration, an effect, which cannot
easily be explained. It can potentially be attributed to an unspeciﬁc
interaction of P-188 with carboxyﬂuorescein.
3.2. Inﬂuence of P-188 on the permeation of poorly soluble model
drugs (ketoprofen and nadolol)
Permeation of the two poorly water soluble model drugs keto-
profen and nadolol was examined both in the absence and in the
presence of P-188. P-188 was used at concentrations of 10, 20
and 50 mg/ml. Each permeation study was repeated three times
with four parallels each. Permeability values in relation to P-188
concentration are given in Figs. 4 and 5. The permeation of both
drugs was found to be signiﬁcantly decreased in the presence of
P-188. For ketoprofen (Fig. 4), a highly reproducible decrease in
Papp with increasing P-188 concentration was observed. For nado-
lol, a similar, yet more variable tendency could be observed (Fig. 5).
This variability may be due to the fact that nadolol is more hydro-
philic. Consequently, the proportion of nadolol that is paracellular-
ly transported compared with the overall permeability is higher
than when compared with ketoprofen, which is more lipophilic.
Interestingly, for batches of monolayers, where the barriers were
leakier, both prior to and after the permeability experiment as
indicated by a relatively lower TEER, P-188 induced a stronger
depression of nadolol permeability than for relatively tighter mon-
olayers. Despite this variability, the effect was apparent in all
parallels.
3.3. Equilibrium permeation of ketoprofen and nadolol
Ketoprofen and nadolol were chosen as model drugs for the
passive permeability pathways. In order to see whether a directed
transport was involved, Caco-2 cell monolayers were incubated
over 4 h with drug solution of the same concentration at the apical
and basolateral side. As expected, the equilibrium was not dis-
turbed for ketoprofen and nadolol, while the P-gp-substrate rhoda-
mine 123 showed the expected accumulation on the apical side
(Fig. 6). This allows the assumption that ketoprofen and nadolol
are passively transported at the concentrations tested in our model
here and that interactions with active transporters can be
neglected.
3.4. Quantitative analysis of the fraction of free drug upon separation
from micelle-bound drug
In order to ﬁnd out whether or not the two model drugs keto-
profen and nadolol interact with surfactant micelles, ultraﬁltration
across cellulose ﬁlters was employed to separate molecularly dis-
solved drug from its micelle-associated form. The chosen cut-off
(MWCO = 10 kDa) was expected to be such that surfactant micelles
would not pass. The concentration of drug in the ultraﬁltrate was
quantiﬁed in comparison with that prior to fractionation. The
Fig. 2. Trans-epithelial electrical resistance (TEER) according to the time in the
absence (control) and presence of P-188 (Poloxamer 188). Triton X-100 (1%v/v)
served as positive control. Data are given as percentage of the initial TEER (prior to
experiment). Values are given as mean ± SEM, nP 8 for the control and P-188
experiments, and n = 5 for Triton X-100.
Fig. 3. Apparent permeability (Papp) of carboxyﬂuroescein in the absence and
presence of different concentrations of Poloxamer 188 (P-188) (P10-P50 = 10, 20
and 50 mg/ml, respectively). Data are given as percentage of the control (concen-
tration of P-188 = 0 mg/ml). Values are given as mean ± SEM, nP 8 for the control
and P-188 experiments, n = 5 for Triton X-100 (1%v/v). Signiﬁcant differences with
the control are marked with  (p < 0.05).
Fig. 4. Permeation of ketoprofen in the presence of different concentrations of
Poloxamer 188 (P-188). Values are given as mean of three independent replicates
with n = 4 each ±SEM, n = 12. Signiﬁcant differences are marked with  (p < 0.05).
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ultraﬁltration results are listed in Table 3. In the absence of surfac-
tant, the concentration in the ultraﬁltrate of both ketoprofen and
nadolol was identical to the initial concentration, which enabled
exclusion of unspeciﬁc loss of drug in the system. In contrast, in
the presence of P-188, the concentrations of both ketoprofen and
nadolol in the ultraﬁltrate were found to be signiﬁcantly lower.
As evidenced from Table 3, there existed a correlation between
surfactant concentration and fraction of micelle-bound drug. As
expected, the more lipophilic ketoprofen showed a stronger ten-
dency to associate with P-188 micelles than nadolol.
4. Discussion
Our permeability studies with the model drugs ketoprofen and
nadolol showed a signiﬁcant decrease in apparent permeability for
both drugs in the presence of P-188. The effect was dependent on
the surfactant concentration.
In contrast, the vast majority of cellular drug permeability stud-
ies report a permeability enhancing effect of both ionic and non-io-
nic surfactants [30–32]. However, these effects were often
accompanied by a decreased trans-epithelial electrical resistance
(TEER) and/or cell viability. In our case, where both impaired cell
viability and/or monolayer integrity was ruled out by stringent
controls, the opposite effect was seen. Under conditions where
an unaffected mannitol-ﬂux and TEER conﬁrmed integrity of the
cell monolayer, Saha et al. found for three proprietary drug com-
pounds either no effect or a permeability enhancement with P-
188 (1%) using the Caco-2 cell-model [17]. But controls on whether
the drug compounds were subject for other pathways than trans-
cellular diffusion were not reported. In another study, a complex
interaction of passive and active drug transport with various
non-ionic surfactants of the poloxamer type was observed [33]:
poloxamers were found to be permeability enhancers, mostly
due to inhibition of efﬂux pumps in connection with a lowering
of membrane ﬂuidity [29,34]. For the drugs in our study design,
carrier-mediated transport was proven to be irrelevant, and a P-
188 effect on the latter can thus be ruled out. There are few studies
where comparable surfactants were shown to retard permeation:
Neuhoff et al. reported a decrease in Caco-2 permeability of felo-
dipine in the presence of Cremophor [35]. Katneni et al. reported
for the poorly soluble drug diazepam an inverse correlation of ex-
cised rat jejunum permeability with micellar solubilization using
polysorbate 80 and polyoxyl 35 castor oil [36]. This effect was
attributed to the reduced thermodynamic activity of the drug,
and/or the fact that the micelle-bound fraction of drug is not read-
ily permeable.
We found that the micellar fraction of drug, as determined by
ultraﬁltration experiments (Table 3) correlated with the surfactant
concentration, for both ketoprofen and nadolol. Despite the facts
that the more lipophilic ketoprofen associated with P-188 micelles
to a higher percentage than nadolol and ketoprofen being more
permeable than nadolol, a signiﬁcant P-188-induced depression
of drug permeability was seen with both drugs. This may indicate
that micellar encapsulation is one possible reason for suppressed
permeability but not the only one.
Fig. 5. Three independent sets of nadolol permeability at different concentrations
of Poloxamer 188 (P-188). Values are given as mean ± SEM, n = 4. Signiﬁcant
differences are marked with  (p < 0.05).
Fig. 6. Equilibrium of drug after 4 h of incubation. Concentrations of drugs were 7.5,
2.6, 0.05 and 0.02 mM for nadolol, ketoprofen, rhodamine 123 (Rho123) and
carboxyﬂuorescein (CF), respectively.
Table 3
Free amount of drug in P-188 solutions (n = 3).
Compound Medium Mean initial
concentration
± SEM (mM)
Mean concentration in
ultraﬁltrate
± SEM (mM)
Fraction of non-
micellar drug a (%)
Ketoprofen HBSS++ 4.43 ± 0.03 4.36 ± 0.02 98.4 ± 0.2
P-188 10 mg/ml 4.37 ± 0.04 4.18 ± 0.05* 95.6 ± 0.3
P-188 20 mg/ml 4.45 ± 0.04 4.05 ± 0.08* 91.0 ± 1.8
P-188 50 mg/ml 4.42 ± 0.10 3.69 ± 0.04* 83.5 ± 2.0
Nadolol HBSS++ 8.04 ± 0.11 8.02 ± 0.06 99.8 ± 1.2
P-188 10 mg/ml 8.04 ± 0.04 7.91 ± 0.06 98.4 ± 0.3
P-188 20 mg/ml 8.06 ± 0.14 7.73 ± 0.04* 95.9 ± 1.5
P-188 50 mg/ml 8.19 ± 0.02 7.80 ± 0.11* 95.3 ± 1.0
P-188 (Poloxamer 188) was dissolved in HBSS++.
a The fraction of non-micellar drug is calculated as the concentration of the ultraﬁltrate divided by the initial concentration and given as percentage.
* Signiﬁcant differences of the ultraﬁltrate concentrations are marked with (p 6 0.05).
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In total, micellar drug incorporation was relatively low, which
might be due to the fact that all solutions were adjusted to pH
7.4. Hence, the drugs were (partly) charged and thus better soluble
in the water phase. But it should be emphasized that drug incorpo-
ration was studied when all drug was dissolved, which was possi-
ble at the chosen pH.
Surprisingly, we observed a decrease in carboxyﬂuorescein per-
meability, at the highest P-188 concentration (50 mg/ml) used,
although carboxyﬂuorescein due to its hydrophilicity is not ex-
pected to associate with P-188 micelles. Thus, micellar association
should not be the only reason for the observed decreased perme-
ability. One may speculate that the decrease in carboxyﬂuorescein
permeability might be due to either a change in viscosity of the
aqueous donor compartment or an unspeciﬁc interaction with P-
188. At the same time, there was no increase in TEER across the
monolayer seen at any P-188 concentration, indicating unaltered
tight junctions.
5. Conclusions
Based on the above ﬁndings with the Caco-2 model, where
stringent controls conﬁrmed both monolayer integrity and cell
viability, it could be shown that the non-ionic surfactant Polox-
amer 188 depressed permeability of the two model drugs ketopro-
fen and nadolol. Both ketoprofen and nadolol are described in
literature not to be substrates of active transport mechanisms, a
conclusion that is supported by our equilibrium studies. Thus,
the P-188-induced change in drug permeability observed here is
not regarded to be due to an interaction of P-188 with transporters.
Furthermore, the fact that P-188 does not signiﬁcantly inﬂuence
TEER renders a direct interference of P-188 with tight junctions
unlikely. Both permeability depression and the extent of micelle
association of the drugs were found to correlate with surfactant
concentration suggesting that the latter is one reason for the re-
duced drug permeability. The innovative aspect of the present
study is the investigation of micellization on passive absorption
in combination with an attempt to systematically rule out other
potential explanations for the observed effect. It remains to inves-
tigate whether these observations hold true for other surfactants
and additional drugs. If so, micellar solubilization of a drug should
reduce its ability to diffuse across Caco-2 monolayers via the trans-
cellular and/or paracellular pathway(s).
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